MassGeneral Institute for Neurodegenerative Disease (MIND)

Overview

Mass General Institute for Neurodegenerative Disease (MIND) is committed to finding treatments to improve the lives of patients with neurodegenerative disorders like ALS, Alzheimer's disease, Huntington's disease and Parkinson's disease.

The Institute's mission is to accelerate research discoveries that will lead to treatment and cures for neurodegenerative diseases. At MIND, a team of world-renowned experts and young, innovative researchers are working in a center that allows them to collaborate, strategize, and share technology to move from basic research to treatment for these diseases. As promising leads are developed in one area, they can be tested in the other neurodegenerative disorders.
Bradley Hyman, MD, PhD and Rudy Tanzi, PhD, lead MIND and carry out the original vision of MIND founder Anne Young, MD—to create open laboratory space with a layout that fosters collaboration and discovery. Together they motivate, inspire and lead the MIND team to achieve a singular goal—bench to bedside research resulting in treatments and cures for neurodegenerative diseases.

Support MIND. Your contributions help drive discovery and propel findings from the laboratory bench into the clinic.

Training at MIND

Students interested in pursuing doctoral studies can find more information about PhD programs through Harvard Medical School.

Current undergraduates or doctoral students interested in undergraduate research opportunities or postdoctoral studies should contact MIND principal investigators directly.

Clinical fellowships that include training in Memory Disorders at MGB are available for individuals who have completed their Neurology residencies – please contact Dr Teresa Gomez-Isla; specialized postgraduate clinical and research training in Neurodegenerative disease neuropathology is also available – please contact Dr Matt Frosch.